Social Risk and Poor CV Health in Community-Dwelling Older ... The Cardiology Advisor
Visit link:
Social Risk and Poor CV Health in Community-Dwelling Older ... - The Cardiology Advisor
April 06, 2023
10 min read
Healio Interviews
Disclosures: Albert, Lichtenstein, Mitter and Weintraub report no relevant financial disclosures. Coylewright reports receiving funding and consultant support from Edwards Lifesciences. Harrington reports receiving consultant fees/honoraria from Atropos Health, Bitterroot, BridgeBio, Bristol Myers Squibb, Element Science, Foresight and WebMD; having a fiduciary role in Cytokinetics; and receiving research grants from CSL Behring, Edwards Lifesciences and Janssen.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Back to Healio
The American College of Cardiology Scientific Session was held March 4 to 6 in New Orleans. Healio | Cardiology Today was on-site for the latest news in cardiology and experts reactions to it.
Among those who offered their insights were American Heart Association President Michelle A. Albert, MD, MPH, FAHA, from the University of California, San Francisco; Megan Coylewright, MD, MPH, FACC, FSCAI, from Erlanger Health System; Robert A. Harrington, MD, FAHA, from Stanford University; Alice H. Lichtenstein, DSc, from Tufts University; Sumeet S. Mitter, MD, from Icahn School of Medicine at Mount Sinai; and Howard Weintraub, MD, from NYU Langone Health.
Editors Note: All coverage from the ACC Scientific Session can be found here .
Howard Weintraub
Weintraub: This study is relevant and important because it demonstrates the efficacy and safety of bempedoic acid (Nexletol, Esperion Therapeutics), a relatively new nonstatin drug that effectively lowers LDL, and it is well tolerated by patients who are statin intolerant. Further, it shows that when this drug is used in these patients, it was able to reduce the frequency of major adverse CV events such as the need for cardiac surgery, fatal heart attacks, CV death and nonfatal stroke.
The study included 13,970 adults from 1,250 sites across 32 countries who were unable or unwilling to take statins owing to unacceptable adverse effects and had or were at high risk for CVD. At a median of 40.6 months, the primary endpoint of CV death, nonfatal MI, nonfatal stroke or coronary revascularization was lower with bempedoic acid than with placebo (11.7% vs. 13.3%; HR = 0.87; 95% CI, 0.79-0.96; P = .004). Similarly, incidence of CV death, nonfatal MI and nonfatal stroke was lower with bempedoic acid vs. placebo (HR = 0.85; 95% CI, 0.76-0.96; P = .006), as was fatal or nonfatal MI (HR = 0.77; 95% CI, 0.66-0.91; P = .002) and coronary revascularization (HR = 0.81; 95% CI, 0.72-0.92; P = .001).
These findings are significant because they demonstrated that there is a drug that is useful and safe in a population of patients that frequently go untreated. It also demonstrated that even a modest amount of LDL reduction over a 3.5-year period was able to have a very meaningful impact on CV risk. Finally, and very importantly, it was one of the few studies to include a large proportion of women. Women comprised 48% of the participants in this trial, and 46% of the patients had diabetes.
This could be practice changing because many patients are reluctant to use any of the cholesterol-lowering medications due to adverse symptoms with the use of statins. Two important differences were the low incidence of muscle aches and the low incidence of the development of type 2 diabetes. Muscle aches are the most common adverse events from statins, but the development of type 2 diabetes is also reported. There were slightly more patients with elevated liver enzymes, and elevations in uric acid were much more frequent.
In this trial, researchers studied patients who have had prior CV events as well as those at increased risk for an event. Both groups saw a meaningful reduction in the combined endpoint. The population of patients who are statin intolerant or perceived as statin intolerant is not a small number of patients. It would be good to have a drug that has been proved in this population but has been shown to reduce events.
There is also the possibility to combine ezetimibe with bempedoic acid. This is available as a single pill and has been shown in clinical trials to lower LDL by as much as 35% to 38%.
Megan Coylewright
Coylewright: It is really challenging to take care of people with severe tricuspid regurgitation. They suffer, and we have limited medical therapies to offer. Most of these patients are elderly and frail and it is very difficult for them to take high-dose diuretics. We dont typically offer surgery for isolated functional tricuspid regurgitation. This is a huge unmet need.
Cardiologists and physicians are very hopeful that we can make people feel better. In the methods, the authors describe that an improvement in quality of life was 15 points on the Kansas City Cardiomyopathy Questionnaire (KCCQ). We usually define a change of 10 points as a moderate improvement. John Spertus, MD, Suzanne Arnold, MD, and others wrote a JACC State of the Art review in 2020 that walks us through this patient-reported measure, including its use in trials. They note that mean differences can be difficult to interpret, as opposed to the proportion of patients who experienced a benefit, for example.
The primary endpoint of TRILUMINATE a composite of mortality or tricuspid valve surgery, hospitalization for HF and quality of life improvement of at least 15 points using the KCCQ, evaluated at 1 year in a hierarchical fashion was met, demonstrating superiority of transcatheter edge-to-edge repair (TEER) over medical therapy alone (win ratio = 1.48; 95% CI, 1.06-2.13; P = .02).
Results did not show a difference, at 1 year at least, in the outcomes of mortality or need for surgery (TEER group, 90.6%; medical therapy group, 89.4%; P = .75) or HF hospitalization (85.1% vs. 87.9%, respectively; P = .41). We are not seeing a large change in quality of life either. I would say thats counter to some of our own experiences in the clinic after performing this procedure; we really see that patients are feeling a lot better. There is a chance our own experience of people feeling better, and the trial results may be limited by not having a sham control.
One thing were all very curious about is what success looks like for interventional HF trials. Were learning as we go along about how to define success when it comes to quality of life. In interventional cardiology, we have recruited tens of thousands of people and measured mortality or measured receiving another stent. Were now partnering with our HF colleagues to understand a little bit more of this space that is driven by quality of life. When we hear the results from TRILUMINATE, were wondering, is an increase in a KCCQ quality of life score of 12 points meaningful enough to lead to a device approval and therefore a change in our clinical practice? People are excited that it is safe, but we also need to be helpful. If were going to sit a patient down and go through a shared decision-making discussion where we discuss the pros and the cons and listen to whats most important to them, if we cannot communicate that theyre going to feel better, then there wont be an indication to go forward with the therapy.
I dont think this trial means that tricuspid repair is unhelpful. Its 1-year follow-up. We have to look closely at the patients that were included, but we also have to think about whether the ways that were measuring quality of life are adequate. Is the KCCQ quality of life score enough to reflect some of the outcomes of my patients who underwent tricuspid repair, like the ability to reduce diuretic dosing, or the ability to bend over and tie their shoes, or the ability to get out of the car without two grandkids lifting them out? These are life-changing for the patients.
Robert A. Harrington
Harrington: NUDGE-FLU is a very interesting study. The researchers looked at whether behavioral nudging would be a viable strategy to boost vaccination update on a population level. More than 964,000 individuals aged 65 years and older (mean age, 74 years; 51% women) in Denmark were randomly assigned to one of nine electronic letters or usual care, which was standard annual correspondence about influenza vaccination from the Danish Health Authority. Communications were delivered before the 2022-2023 influenza season via the countrys governmental electronic letter system.
Subsequent influenza vaccine uptake was higher in two groups: those who received the electronic letter highlighting the potential CV benefits (81% vs. 80.12%; P < .0001) and those who received a reminder letter 2 weeks after the first (80.85% vs. 80.12%; P = .0006).
We did something in our health system a few years ago that was very similar to try to nudge people with different types of contact. That was a localized health system, but this is a much bigger effort. You cant do a countrywide effort everywhere, but in certain health systems, you can. The sheer scope was impressive.
Also impressive was the different types of behavioral nudges, and that the researchers actually got a result that showed that something might be effective. Perhaps not surprisingly, giving people insight into flu vaccine lowering direct risk for CVD was one of the winners. For cardiologists, that felt good. I thought the social-good option might win, given the perception of Scandinavian countries placing a priority on doing things for the social good.
Not surprising from a human behavior perspective is that if you do something repeatedly, you increase the yield.
This is actionable. In the U.S., it may be hard to get this at the national level, but we can get it at the county level. It would be nice to see something like this rolled out in counties across the U.S. I could also see individual health systems doing this. I get texts from my county about road closures; why couldnt I also get one reminding me to get my flu shot?
The one caution is that Danes are more ethnically homogenous in terms of racial backgrounds, experiences, socioeconomics, etc, than we are in the U.S. It would be nice to see more data across difference racial and socioeconomic subgroups, because of the hypothesis that different behavioral nudges may work in different groups.
Michelle A. Albert
Albert: A number of patients from diverse clinical backgrounds still do not get to optimal LDL levels on statins alone. Adding a PCSK9 inhibitor on top of statins allows them to get closer to optimal levels. It is an important alternative for people who cannot get to optimal levels on statins and for people who are intolerant to higher doses of statins. Adding something on top of statins can be very effective.
The study population was at intermediate to high risk for coronary disease and about 55% had diabetes. Despite so many of these patients having diabetes, only 20% were taking a high-intensity statin in accordance with guidelines. A lot more of these patients should have been on high-intensity statins; it should parallel close to the percentage of those with diabetes.
The researchers randomly assigned 381 participants to placebo or one of four doses of the oral PCSK9 inhibitor: 6 mg, 12 mg, 18 mg or 30 mg, all once daily.
At 8 weeks, the differences in least squares mean percentage change in LDL compared with placebo were as follows:
What was very intriguing is that lipoprotein(a) levels in those who took the oral PCSK9 inhibitor were lowered by about 20%, even though that was not what the researchers were looking to study. That is important for the Black population, who have higher Lp(a) levels than other groups.
There were very few Black people in this study, but it was gratifying to see that each assignment group was 17% to 23% Asian, and there were a few American Indian/Alaska Native participants, who are traditionally not well represented in studies.
Sumeet S. Mitter
Mitter: The most important take-home message from the STOP-CA trial is that statins potentially could help attenuate the drop in the EF among patients exposed to anthracyclines for lymphoma.
Unfortunately, with anthracyclines, which patients need to treat their malignancy in lymphoma or breast cancer, sometimes there are off-target effects, such as damage to the heart muscle. Weve been trying to find ways to attenuate the drop in EF and eventual HF events.
Prior to anthracycline treatment, 300 patients were assigned atorvastatin or placebo for 12 months. The primary outcome of the proportion of participants with a decline in LVEF of 10% to less than 55% at 12 months was 9% in the atorvastatin group compared with 22% in the placebo group (P = .002). The likelihood of decline in cardiac dysfunction after anthracyclines was nearly threefold among patients randomly assigned placebo (OR = 2.9; 95% CI, 1.4-6.4).What it means for patients is that potentially there may be a push to start high-dose statins such as atorvastatin 40 mg in this trial to attenuate that drop in EF.
What we dont know from STOP-CA, and what I think most cardiologists will be wanting from this and looking forward prospectively in further studies, is will this also amount to a reduction in HF events? There is a dichotomy there in what this implies, more so in patients receiving placebo vs. those receiving atorvastatin; we didnt necessarily measure the actual HF syndrome, event, hospitalization or quality of life, here. That is very different from what we interpret on an echocardiogram. Ultimately, the magnitude of difference in the mean EF between two arms is only 1%, which frankly is not that much in terms of clinical meaning.
The future is bright though. If we continue to conduct well-performed studies looking at agents that could help attenuate the drop in EF, we may one day find also a therapy that stops a drop in EF that may result in reduction of HF events, but ultimately will also be associated with a reduction in HF events and overall improvement in survival and quality of life for our patients afflicted with these malignancies.
Alice H. Lichtenstein
Lichtenstein: In a study of 305 participants who followed a keto-style diet and 1,220 who followed a standard diet who were not on lipid-lowering therapy, the overall prevalence of severe hypercholesterolemia (> 5 mmol/L) was higher among individuals who followed a keto-style diet (11.1% vs. 6.2%; P < 001). The risk for incident ASCVD events was more than twofold among patients following a keto-style diet compared with a standard diet (HR = 2.18; 95% CI, 1.39-3.43; P < .001).
The outcome of long-term consumption of a keto-style diet likely depends on the type of foods hence, the type of fat that predominates. If animal fat meat and milk fat predominates, high in saturated fat, it is not surprising the researchers reported a positive association with elevated CVD risk. Given LDL cholesterol levels were higher, that is likely the case in this study. If a person decides to follow a keto-style diet and gets their fats predominantly from plant sources, high in unsaturated fat such as plant oils soybean, canola, corn, olive, nuts and seeds it is very possible the results will be different.
There is a paper that recently came out in Diabetes Care in patients with type 2 diabetes that supports this premise (Hu Y, et al. Diabetes Care. 2023;doi:10.2337/dc22-2310).
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Back to Healio
More:
Vincent M. Figueredo, Blue Bell cardiologist, has written a book that chronicles the discovery of the hearts anatomical role. The Wall Street Journal excerpted it.
Figueredos cardiological history dates to 1641 and a shocking medical case in England. Patient Hugh Montgomery had sustained a childhood injury that left his beating heart visible through a gap in his chest.
Montgomery became something of a celebrity, allowing strangers to view his cardiac activity firsthand. He even showed it to King Charles I, who painlessly touched the organ as it dutifully pumped.
That visible evidence started to shift the hearts established view, which was then theorized to be much closer to the activities now attributed to the brain: emotions, passion, intelligence.
The hearts true function moving blood for oxygenation purposes started to emerge.
Harvey ran several experiments to test the heart-as-pump theory. He worked with tourniquets and live subjects (inmates and animals) to confirm that the organ was, indeed, little more than an array of muscles and valves designed to move blood.
At the diastole it was drawn in and retracted; and in the systole, it came forth and was thrust out, read his notes from the time.
More on the evolution of cardiological education from Blue Bells Vincent M. Figueredo is at The Wall Street Journal.
_____
A history of cardiology presented at University College London.
View post:
Vincent Figueredo, Blue Bell Cardiologist, Writes Book on the Heart - BUCKSCO.Today
Text Messaging Program Increased Smoking Cessation Rates at 6 ... The Cardiology Advisor
See more here:
Text Messaging Program Increased Smoking Cessation Rates at 6 ... - The Cardiology Advisor
Newswise LOS ANGELES (April 7, 2023) --Two Smidt Heart Institute experts have been honored for their contributions to medical research by being inducted into select medical societies, while a third expert has been selected for a leadership position.
Cardiologist, echocardiographer and clinician-scientistSusan Cheng, MD, director of Cardiovascular Population Sciences in theSmidt Heart Instituteand the Erika J. Glazer Chair in Womens Cardiovascular Health and Population Science, has been elected to the American Society for Clinical Investigation (ASCI) Council.ASCI is regarded as the most prestigious honorary society in internal medicine, andCheng is one of only two U.S. physicians elected to the council this year.
Cheng leads research programs aimed at uncovering drivers of cardiovascular aging in women and men, why the sexes experience the aging process differently, and how aging leads to different types of heart disease.
Im honored to serve the organization in this capacity, said Cheng, whose term begins April 21,andIm particularly eager to represent Cedars-Sinai on the council as well as to continue my work in the study of sex differences in cardiovascular pathophysiology and disease.
The society also inducted cardiac electrophysiologistEugenio Cingolani, MD, director of the Cardiogenetics Program at the Smidt Heart Institute, for outstanding achievement in academic medicine.
Cingolani, whose most recently published study explored how to create biological pacemakers by reprogramming heart cells to make them beat spontaneously, is among the societys 100 new active and international members from 49 institutions. Cingolani and his peers will be inducted into the society during a special ceremony Friday, April 21, in Chicago at a joint meeting with the Association of American Physicians and the American Physician Scientists Association.
The American Society for Clinical Investigation is a nonprofit medical honor society comprising more than 3,000 physician-scientists from all medical specialties. The society is dedicated to advancing research that extends understanding of diseases and improves treatment; members are committed to mentoring future generations of physician-scientists.
Founded in 1908, the organization is one of the nations oldest medical honor societies and is among the few focused on the special role of physician-scientists in research, clinical care and medical education, as well as leadership positions in academic medicine and the life sciences industry.
Improving heart health through novel research and treatment protocols is among my greatest passions, said Cingolani, also an associate professor of Cardiology and director of Preclinical Research at Smidt Heart Institute, and recognition for that from the ASCI is a career highlight.
Damini Dey, PhD, directorof the Quantitative Image Analysis Program in theBiomedical Imaging Research Instituteat Cedars-Sinai,has been inducted into the 2023 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellowsrecognition that is reserved for the top 2% of medical and biological engineers.
Dey, professor of Biomedical Sciences at Cedars-Sinai and co-associate director of the Biomedical Imaging Research Institute, wasnominated, reviewed and elected by peers and members of the AIMBE College of Fellows for her pioneering contributions in artificial intelligence analysis of cardiac images to predict and prevent heart attacks. Dey was formally inducted March 27 in Arlington, Virginia, as part of the groups annual meeting.
TheAmerican Institute for Medical and Biological EngineeringCollege of Fellows honors those who have made outstanding contributions to engineering and medicine research, practice or education and to the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering or developing/implementing innovative approaches to bioengineering education.
What an incredible honor to receive this recognition, Dey said. Ive always been impressed by the mission of the organization, in particular its commitment to accelerating medical and biological innovation. I look forward to continuing my research emphasis on AI and machine learning in cardiac imaging to predict heart attack risk and to precisely quantify the effect of prevention strategies.
Dey is among 140 colleagues who make up the AIMBE College of Fellows Class of 2023. Inductees have previously included Nobel Prize laureates and Presidential Medal of Science and/or Technology and Innovation recipients.
My congratulations to Dr. Cheng, Dr. Cingolani and Dr. Dey on receiving such prestigious acknowledgement from two highly regarded organizations on their incredible clinical and research contributions to our understanding, diagnosis, treatment and prevention of cardiovascular diseases,saidJeffrey Golden, MD, vice dean of Research and Graduate Education and director of the Burns and Allen Research Institute at Cedars-Sinai.The recognition is admirable, as is their commitment to advancements in heart health.
The Smidt Heart Institute is ranked #1 in California and #3 in the nation for Cardiology & Heart Surgery inU.S. News & World Reports Best Hospitals 2022-23.
Read More On The Cedars-Sinai Blog:A New Partner In Heart Disease Prediction: AI
Excerpt from:
Cedars-Sinai Heart Experts Elected to Lead, Join Prominent Medical Societies - Newswise
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and the American College of Cardiology (ACC) today released the latest NCD Academy course, Health Equity and Social Determinants of Health in NCDs, coinciding with World Health Day and the theme Health for All. The NCD Academy is a user-friendly, interactive online platform developed by the ACC in partnership with the NCD Alliance and the World Heart Federation and sponsored by Viatris. The program is designed to equip primary healthcare professionals with educational resources and skills to enhance their ability to prevent and treat non-communicable diseases (NCDs). The NCD Academys overarching goal is aligned with the vision to make health for all a reality, by providing continued education for skilled health workers and supporting people-centered care.
Health equity, as described by the WHO Commission on Social Determinants of Health (CSDH), is the absence of inequalities in healthcare that are avoidable by reasonable means. The new Health Equity and Social Determinants of Health in NCDs course aims to educate and increase awareness of health inequities and provide support on how to address them to achieve equitable care for all. Course topics led by leading experts in global health equity include an overview of social determinants of health; a closer look at the impact of structural discrimination; and strategies for tackling disparities in vulnerable communities, as well as low- and middle-income countries.
Health equity and broadening access to healthcare is core to Viatris mission of empowering people worldwide to live healthier at every stage of life. We are proud to collaborate with our NCD Academy partners to support the launch of the new course on Health Equity, as part of our continuing efforts to deliver access to health education on a global level, said Lobna Salem, Head of Medical Affairs, Developed Markets. NCDs account for over 70% of deaths globally, many of which are preventable. Viatris is committed to helping to reduce this number, as demonstrated through one of our initial sustainability goals announced in our 2021 Sustainability Report: to impact 100 million patients via HCP education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025.
Launched in 2020, the NCD Academy features courses on nearly all aspects of NCDs, including cardiovascular disease and cancer. More recent courses also address mental health and advocacy and their respective roles in the NCD crisis, from which no country is immune. The new Health Equity course is being rolled out throughout the month of April, available at ACC.org/NCDAcademy.
Health equity is a critical global health issue that must be addressed if we are to truly stem the tide of NCDs, said Dipti Itchhaporia, MD, MACC, former ACC president and a past chair of the Colleges Health Equity Task Force. Transforming cardiovascular care and improving heart health for all needs to start with solving for health equity. The ACC is proud to partner with Viatris, WHF and NCD Alliance to drive awareness and action around this important topic. Together we are delivering global education that inspires global action and, while there is still much work to be done, it is exciting to see how far weve come to date.
For more information about the NCD Academy and to view available courses visit ACC.org/NCDAcademy.
About the NCD Academy
NCD Academy equips healthcare professionals, such as general practitioners, internists, nurses and community health workers, with high-quality continuing education availableanytime, anywhere, and free of chargeon fundamental skills to prevent, manage and mitigate today's leading causes of death and disability. Courses address non-communicable diseases (NCDs) through an intersectional lens given shared risk factors and the tendency of NCDs to coexist with one another, as well as with infectious diseases. Courses include eLearning that emulates the experience of intensive face-to-face training through interactive knowledge application and practice in the form of patient cases and games such as trivia. The Academy has hosted 44 trainings, equipping more than 70,000 health care professionals across ten countries with the latest science, technology, resources and tools to manage and prevent NCDs. The program has reached physicians and patients across many countries including Argentina, China, Colombia, Egypt, India, Iraq, Mexico, Peru, the Philippines, Saudi Arabia, Spain and the United States.
About the American College of Cardiology
The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. Asthe preeminent source of professional medical education for the entire cardiovascular care team since 1949,ACCcredentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines.Through its world-renowned family ofJACCJournals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring aworld where science, knowledge and innovation optimize patient care and outcomes. Learn more at ACC.org or follow @ACCinTouch.
About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.
Contacts:
ACC:Nicole Napolinnapoli@acc.org
Viatris:Media:+1.724.514.1968Communications@viatris.com
Matt KleinMatthew.Klein@viatris.com
Investors: +1.724.514.1813InvestorRelations@viatris.com
Bill SzablewskiWilliam.Szablewski@viatris.com
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
Excerpt from:
NCD Academy launches new Health Equity and Social ... - EurekAlert
April 03, 2023
3 min read
Disclosures: Fuchs reports no relevant financial disclosures. McDermott and Newby report receiving grants and funding from the British Heart Foundation. Please see the study for all other authors' relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Back to Healio
Subclinical, obstructive coronary atherosclerosis was linked to a more than 8-fold elevated risk for myocardial infarction in asymptomatic adults aged 40 years or older, according to researchers.
Andreas Fuchs, MD, PhD, of the department of cardiology at Copenhagen University HospitalRigshospitalet, and colleagues wrote that coronary atherosclerosis can develop at an early age and remain latent in the body for many years.
Coronary atherosclerosis is the key pathobiological process that is responsible for the development of myocardial infarction, and together, these conditions define ischemic heart disease, the researchers wrote. Subclinical coronary atherosclerosis comes before ischemic heart disease, and can evolve at an early age, even years before the clinical disease develops.
For more than 50 years, obstructive coronary artery disease, defined as a luminal coronary stenosis of 50% or greater, has been considered a key feature of elevated risk, they wrote. In the past decades, however, the extent of atherosclerosis in the coronary tree as well as specific morphologic features of the atherosclerotic plaque have been acknowledged as important risk factors.
Fuchs and colleagues conducted a prospective observational cohort study to define characteristics of subclinical coronary atherosclerosis linked to the development of MI in 9,533 asymptomatic participants aged at least 40 years without CVD. Their findings were recently published in Annals of Internal Medicine.
We tested the hypothesis that characteristics of subclinical coronary atherosclerosis are associated with an increased risk for MI in asymptomatic persons without known ischemic heart disease, they wrote.
The researchers used coronary computed tomography angiography to assess subclinical coronary atherosclerosis. Coronary atherosclerosis was then characterized by extent and luminal obstruction (obstructive being defined as greater than 50% luminal stenosis).
Fuchs and colleagues found that just over half 54% of the participants did not have subclinical coronary atherosclerosis, and, of the 46% who did, 10% had obstructive disease. Additionally, of those diagnosed, the condition was found more frequently in men than women (61% vs. 36%).
The researchers noted that, in the median follow-up of 3.5 years, 71 participants had an MI and 193 died. MI risk was higher in those with obstructive (adjusted relative risk [aRR] = 9.19; 95% CI, 4.49-18.11) and extensive (aRR = 7.65; 95% CI, 3.53-16.57) disease and highest in those with both extensive and obstructive subclinical coronary atherosclerosis (aRR = 12.48; 95% CI, 5.50-28.12) or obstructive-nonextensive (aRR = 8.28; 95% CI, 3.75-18.32).
Obstructive subclinical coronary atherosclerosis was associated with a more than 8-fold increased risk for MI, and the risk for either death or MI was increased 2-fold in persons with extensive subclinical coronary atherosclerosis, they wrote.
Fuchs and colleagues also wrote that, regardless of degree of obstruction, the risk for the composite end point of death or MI was increased in those with extensive disease: obstructive-extensive (aRR = 3.15; 95% CI, 2.05-4.83) and nonobstructive-extensive (aRR = 2.7 95% CI, 1.72-4.25).
Identification of luminal obstructive or extensive subclinical coronary atherosclerosis, which we have shown are associated with high risk, provides potentially clinically relevant, incremental risk assessment in patients without suspected or known ischemic heart disease undergoing cardiac CT and/or electrocardiogram-gated chest CT for other clinical indications, they wrote.
In an accompanying editorial, Michael McDermott, MBChB, a cardiology research fellow at the University of Edinburgh, and David E. Newby, DM, PhD, British Heart Foundation Duke of Edinburgh Chair of Cardiology, wrote that this exceptional and important study now provides a benchmark against which to observe the contemporary natural history of coronary artery disease.
It also provides invaluable data about event rates and prevalence of asymptomatic coronary artery disease that will inform public health prevention strategies and ongoing clinical trials of targeting preventative therapies in persons screened for occult coronary artery disease, McDermott and Newby wrote.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Back to Healio
Read the original here:
Asymptomatic coronary atherosclerosis linked to 8-fold higher risk ... - Healio
Introduction
In the recent literature, cardiology based training in different procedures and techniques has been garnering a lot of attention.13 As of 2019 over 90,000 physicians specialize in cardiac-based procedures and interpretation in the United States. One such procedure is echocardiography, and physicians who specialize in interpreting them are called primary echocardiographers, which include cardiologists and radiologists.4 22,521 active physicians practice in the field of cardiology and 28,025 active physicians practicing in radiology.5 In comparison, there are only 1667 anesthesiologists who practice cardiac anesthesia as a subspecialty.6 Subspecialization in cardiac anesthesiology requires at least 4 years of training in an anesthesiology residency program and at least 1 year of a cardiac anesthesiology fellowship.716
During their residency and fellowship years, most anesthesiologists will be trained in the use of echocardiography. One such type of echocardiography is transthoracic echocardiogram (TTE), in which a handheld transducer is held outside the heart.17,18 Although other forms of echocardiograms exist, such as intracardiac echo and stress echo, a transesophageal echocardiogram is often the approach in the perioperative setting. Compared to TTE, a transesophageal echocardiogram can be more sensitive at identifying etiologies of an embolic stroke.1921 One study suggests that TEE may be more suitable than TTE for detecting infective endocarditis.22 Transesophageal echocardiograms can assess the hearts function and detect symptoms of atherosclerosis, cardiomyopathy, heart failure, and more.23,24 This is because an ultrasound probe is guided into the esophagus, providing a closer view of the heart.2530 Interpreting TEEs have a significant impact throughout perioperative care in order to make a proper diagnosis.31 Although cardiac anesthesiologists, cardiologists, and radiologists are all trained in interpreting transesophageal echocardiography, an overwhelming majority of perioperative TEEs are performed by cardiac anesthesiologists. A study by Poterack recognized that out of 98 institutions surveyed, 54% of them have anesthesiologists in charge of TEE interpretations.32 Therefore, it is of utmost importance that cardiac anesthesiologists are well-trained in these procedures.
TEE specifically has seen major growth in terms of technology, use, and indications since its introduction to the medical community nearly half a decade ago.33 These advancements include the increase in TEE use from 29% in 2009 to 45% in 2011, and upgrades in technology such as the 3-D TEE systems.34 3-D TEE imaging has been shown to improve detecting infective endocarditis in a study by Chahine et al.35 Additional advancements include continuous TEE monitoring, strain imaging, and diastolic function assessment.36 These advancements have also increased the complexity of the procedure itself. For this reason, diagnostic evaluation of the TEE exams may vary disparately depending on who delivers the procedure and the expertise of the examiner.37 Despite the active role that cardiac anesthesiologists have in the perioperative setting, there is limited literature on the assessment of their ability to interpret intraoperative TEE. Our paper conducts a systematic literature review to assess the effectiveness with which cardiac anesthesiologists interpret TEE examinations compared to primary echocardiographers, such as cardiologists and radiologists.
The PRISMA systematic review model was used to execute this study and identify relevant literature.38 A comprehensive search was used on the MED-LINE database (PubMed) to yield articles used for our study. Step 1 included using a broad keyword search using the phrases Cardiology Anesthesiology Echocardiogram and Echocardiography Anesthesiology to produce 1114 and 684 articles, respectively, dating from 1952 to 2022. The criteria for inclusion and exclusion are shown below in Figure 1 including but not limited to articles being written in the English language.
Figure 1 Study flow chart.
From the search, a total of 363 articles were included based on the relevance of the title (Figure 1, step 1), and duplicates were then removed (Figure 1, step 2). The remaining articles were then screened based on their abstract (Figure 1, step 3). The last step executed was reading the full article to determine which publications will be used in the study (Figure 1, step 4). This process yielded a combination of quantitative and qualitative information that amounted to a total of 9 relevant articles for our topic of interest. Three researchers carried out the procedures to obtain the final sample. The investigation team agreed on the final selection of the literature (Table 1).
Table 1 Publications Included in the Systematic Review
After assembly of the 9 articles, they were divided according to whether they contained quantitative or qualitative data. There were three quantitative data containing the accuracy of cardiac anesthesiologists TEE readings. Accuracy is defined as the degree to which cardiac anesthesiologists TEE interpretation agreed with that of primary echocardiographers. The quantitative studies examined different parameters as part of the TEE procedure and also used different methods to assess accuracy. Cohens kappa coefficient and high-fidelity videotape evaluation were the methods of analysis used to evaluate the accuracy of the interpretation of these parameters. The number of correctly interpreted TEEs and the total number of TEEs were obtained from each of the three quantitative studies. These numbers were then used to calculate the mean accuracy in the interpretation of all TEEs to represent the overall accuracy of cardiac anesthesiologists (Table 2).
Table 2 Results of Transesophageal Echocardiogram Results in Systematic Review
PRISMA systematic review yielded a total of 3 quantitative studies and 6 qualitative studies for a total of 9 relevant studies. The three quantitative studies contained comparisons between cardiac anesthesiologists and radiologists, cardiac anesthesiologists and cardiologists, and cardiologists and radiologists.
Mathew et al contained the concordance rate of TEE interpretations amongst cardiac anesthesiologists, cardiologists, and radiologists. In the study, radiologists interpreted the same number of TEEs as cardiac anesthesiologists. For this reason, we decided to compare anesthesiologists to radiologists in this study. They found that anesthesiologists with less than 5 years of experience underestimated left ventricular fractional area change (FAC). On the other hand, anesthesiologists with greater experience had higher levels of concordance with radiologists, particularly in the assessment of the aorta, right atrium, pulmonary vein flow, and transmitral flow. Furthermore, cardiac anesthesiologists correctly interpreted 83% of TEEs when compared specifically to radiologists. Out of 2464 TEE exams, this comes out to a total of 2045 correctly interpreted TEEs. Nevertheless, comparisons between anesthesiologists and cardiologists (80% concordance) and cardiologists and radiologists (82% concordance) were all similar.
The study by Mishra et al contained information regarding the concordance between online interpretation by cardiac anesthesiologists and offline analysis by cardiologists. This study specifically examined left ventricle regional wall motion, valve function, and left and right ventricle function. 3620 out of 4161 TEEs were correctly interpreted by the cardiac anesthesiologists, amounting to an accuracy rating of 87%. Although this study did not state the number of anesthesiologists involved, they examined 3217 TEEs in a group of patients who underwent coronary bypass graftings and 629 TEEs in a group of patients who underwent valve procedures, yielding a total of 3846 TEEs that were interpreted.
The final quantitative study by Miller et al compared the performance of anesthesiologists to an expert cardiologist in recording and interpreting TEEs. Parameters measured in this study included size of the heart chambers, FAC, and degree of stenosis or insufficiency of heart valves. They found that their cardiac anesthesiologists correctly interpreted 1242 out of 1572 TEEs, a 79% accuracy rating. As indicated in Table 2, these three studies totaled 8197 interpreted TEEs by cardiac anesthesiologists, 84% of which were correctly interpreted.
The American Society of Echocardiography suggests that non-cardiologists such as radiologists and cardiac anesthesiologists who provide optimal TEE services should ideally undergo 6 months of full-time training in an active echocardiography training institution.39 They recommend being involved in 300 total TEE exams and performing at least 150 of those exams, and 15 h of TEE within 3 years per Continuing Medical Education (CME) standards. Thus, all physicians who were not formally trained in TEE should adhere to these standards. It may also be advisable to consider facilitating close interactions between cardiac anesthesiologists and cardiologists or radiologist echocardiographers, at least in the initial training phases.40
In our study design, we chose to compare the evaluation of TEE studies between attending anesthesiologists to primary attending echocardiographers, either cardiologists or radiologists. A prospective observational cohort study was performed between 1993 and 1997 meant to evaluate TEE as a safe and reliable technique during cardiac surgery.41 3217 TEEs were administered to 944 patients who underwent coronary artery bypass grafting (CABG) procedures, and another 629 TEES to 142 patients who underwent heart valve procedures. The attending anesthesiologists who performed the TEE had a minimum hands-on experience of performing and interpreting 500 TEE studies each. Although the study did not disclose the number of anesthesiologists included in the study, they found that there was a rather high concordance between anesthesiologists and cardiologists (87%). This suggests that anesthesiologists can interpret and perform TEE studies in a manner comparable to that of cardiologists.
Another study was done at Duke University Medical Center that assessed the concordance of TEE interpretation in a continuous quality improvement (CQI) program.4 In this study, 10 cardiac anesthesiologists conducted a total of 154 TEE studies that included the estimation of FAC using Bland-Altman methods. Fractional area change is a measure of right ventricular systolic function. It is clinically significant because it can be used to measure any impairments to right ventricle function, such as after a pulmonary valve replacement.42 All 154 of the TEE studies were reviewed by radiologists, 50 of which were also reviewed by cardiologists. Cardiac anesthesiologists were found to underestimate the FAC when compared to radiologists, especially if the anesthesiologist had less than 5 years of TEE experience. Anesthesiologists with more experience, however, were found to have higher levels of concordance with the radiologists. Ultimately, the high levels of concordance of anesthesiologists to radiologists (83%) and cardiologists (80%) suggest that anesthesiologists are proficient in TEE interpretation.
A prospective study done at the Madigan Army Medical Center evaluated the ability of anesthesiologists to perform and interpret TEE after revisions were made to their examination protocol.43 Namely, these revisions entailed going from a standard 10 view TEE examination to a 12 view in which 8 were from the original and 4 assessed with color Doppler. Eight cardiac anesthesiologists performed 135 TEE examinations, which were then compared with a final expert evaluation by a cardiologist, yielding an accuracy of 79%. Although this is considerably lower than the other studies we analyzed, this is inclusive of TEE examinations with omitted diagnoses (blanks on evaluation sheets). If these TEE examinations had not been included in the study, the rate of correct interpretation would have been 94%.
It has been shown in a study done at Aarhus University Hospital that anesthesiologists are capable of providing valuable information in interpreting TEE.44 A TEE was successfully performed on 525 children undergoing cardiac surgery and according to the results, interpretations of TEE performed by anesthesiologists resulted in a total of 184 alterations to treatment in 143 patients. Additionally, anesthesiologists were able to add 37% of new information and add 8% of decisive information out of all the TEEs interpreted.
Although our study indicates how effective anesthesiologists can be in perioperative care, there have been multiple studies that have shown experience and training is still valuable in both carrying out the TEE procedure and interpreting the results. One study compared the length of time it takes to obtain a TEE exam and how accurate the interpretation was between certified anesthesiologists and anesthesiology residents.45 Attending physicians and residents were recruited from both the Vanderbilt School of Medicine and The Icahn School of Medicine at Mount Sinai for a total of 15 residents and 11 attending physicians. Participants were required to obtain 10 standard views using TEE. The certified anesthesiologists were able to interpret 5 out of 10 images better than the residents, whereas the remaining 5 views were comparable to the residents. Results also indicated that certified anesthesiologists were able to acquire TEE images more quickly, suggesting that experience is necessary to become a proficient echocardiographer.
A study done at Mahidol University concurred with this by showing improvement in acquiring TEE images as the procedure was performed more often.46 An additional study performed at The Icahn School of Medicine at Mount Sinai suggested that more experienced anesthesiologists were able to score higher on multiple-choice questions that involved TEEs.47 Evidently, experience in echocardiography improves both the theoretical knowledge and the practical application of the skills involved in TEE.
Limitations to our study include the circumstances of assessment in our quantitative studies. Specifically, comparisons were made between on-line assessments by anesthesiologists and off-line assessments of the primary echocardiographers. It is plausible that there could have been a higher level of agreement between the two groups if they interpreted TEEs under the same circumstances. For example, there may have been higher concordance if the anesthesiologists evaluated TEE results after operation. Another limitation to our study is that most of our quantitative data were published nearly 20 years ago. If these studies were to be done today, it may be the case that we would see higher concordance between cardiac anesthesiologists and primary echocardiographers, especially because of the guidelines that were established since then.39 Another notable limitation of this study is that there were variations in the gold standard for interpreting TEEs. Some studies used expert echocardiographers as the gold standard, while others relied on the degree to which there was consensus amongst attending echocardiographers.
A possible method of improving clinical evaluation is by refining current indications for the use of echocardiography. For example, echocardiography currently plays a major role in the diagnosis and management of infective endocarditis (IE) as part of Dukes criteria. However, many patients are initially misclassified even though IE is a life-threatening emergency.4850 This is partly because a negative echocardiogram does not rule out IE and a false-positive result is not unusual with these tests. The fault here is not so much in the conductor of the test, but the test itself. Therefore, in these cases, it may be worth considering other imaging techniques. An 18F-FDG PET/CT scan has instead shown promising results with these patients.5156
Based on the studies presented, it is clear that anesthesiologists have an important role in the perioperative stages of patient care by performing and interpreting transesophageal echocardiograms. With continuous quality improvement, cardiac anesthesiologists are shown to function at a level equivalent to that of primary echocardiographers. The implementation of software programs to routinely test physician TEE skills and the implementation of standardized AI interpretation as a possible gold standard are noteworthy considerations for future investigation.
The authors declare no competing interests in this work.
1. Zhitny V, Iftekhar N, Alexander L, Ahsan C. Cardiology fellow diagnostic accuracy and data interpretation outcomes: a review of the current literature. Vasc Health Risk Manag. 2020;16:429435. PMID: 33116553; PMCID: PMC7585513. doi:10.2147/VHRM.S266510
2. Kohan LC, Nagarajan V, Millard MA, Loguidice MJ, Fauber NM, Keeley EC. Impact of around-The-clock in-house cardiology fellow coverage on door-to-balloon time in an academic medical center. Vasc Health Risk Manag. 2017;13:139142. PMID: 28458558; PMCID: PMC5403126. doi:10.2147/VHRM.S132405
3. Spahillari A, McCormick I, Yang JX, Quinn GR, Manning WJ. On-call transthoracic echocardiographic interpretation by first year cardiology fellows: comparison with attending cardiologists. BMC Med Educ. 2019;19(1):213. PMID: 31200721; PMCID: PMC6567532. doi:10.1186/s12909-019-1634-7
4. Mathew JP, Fontes ML, Garwood S, et al. Transesophageal echocardiography interpretation: a comparative analysis between cardiac anesthesiologists and primary echocardiographers. Anesth Analg. 2002;94(2):302309. PMID: 11812688. doi:10.1097/00000539-200202000-00013
5. AAMC. Number of people per active physician by specialty; 2019. Available from: https://www.aamc.org/what-we-do/mission-areas/health-care/workforce-studies/interactive-data/number-people-active-physician-specialty-2019. Accessed: June 13, 2022.
6. Adult cardiac anesthesiology. Careers in medicine; 2022. Available from: https://www.aamc.org/cim/explore-options/specialty-profiles/adult-cardiac-anesthesiology?check_logged_in=1#workforce. Accessed June 19, 2022.
7. Massachusetts General Hospital. Guide to cardiac anesthesia; 2022. Available from: https://www.massgeneral.org/heart-center/treatments-and-services/cardiac-surgery/guide-to-cardiac-anesthesia#:~:text=A%20cardiac%20anesthesiologist%20is%20a,a%20cardiac%20anesthesia%20fellowship%20program. Accessed November 21, 2022.
8. Penn State College of Medicine Residencies and Fellowships. Cardiac anesthesia fellowship; 2022. Available from: https://residency.med.psu.edu/programs/cardiac-anesthesia-fellowship/. Accessed March 31, 2023.
9. Department of Anesthesiology. Cardiothoracic anesthesiology fellowship; 2022. Available from: https://anesthesiology.weill.cornell.edu/education/fellowships/cardiothoracic-anesthesiology. Accessed March 31, 2023.
10. Cardiothoracic Anesthesia Fellowship - Brigham and Womens Hospital. Adult cardiothoracic anesthesia fellowship; 2022. Available from: https://www.brighamandwomens.org/anesthesiology-and-pain-medicine/clinical-fellowships/cardiothoracic2/cardiothoracic-fellowship-landing#:~:text=The%20fellowship%20is%20either%2012,%2D%20to%2024%2Dmonth%20program. Accessed March 31, 2023.
11. Cardiothoracic Anesthesiology Fellowship. Anesthesiology; 2022. Available from: https://keck.usc.edu/anesthesiology/training-education/fellowship-programs/cardiothoracic-anesthesiology-fellowship. Accessed March 31, 2023.
12. Department of Anesthesiology, Perioperative and Pain Medicine. Adult cardiothoracic anesthesia; 2022. Available from: https://med.stanford.edu/anesthesia/education/fellowships/clinical-fellows/acta.html. Accessed March 31, 2023.
13. Wdelaney. Adult cardiothoracic anesthesiology fellowship. Medical School - University of Minnesota; 2018. Available from: https://med.umn.edu/anesthesiology/education-training/fellowship-programs/cardiothoracic-anesthesiology-fellowship. Accessed March 31, 2023.
14. Department of Anesthesia & Critical Care | The University of Chicago. Adult cardiothoracic fellowship; 2022. Available from: https://anesthesia.uchicago.edu/education/adult-cardiothoracic-fellowship. Accessed November 21, 2022.
15. Johns Hopkins Anesthesiology and Critical Care Medicine. Cardiac anesthesiology and interventional echocardiography fellowship; 2022. Available from: https://anesthesiology.hopkinsmedicine.org/accm-homepage/cardiac-anesthesia/cardiac-anesthesia-fellowship/. Accessed November 21, 2022.
16. Adult Cardiothoracic Anesthesiology (ACTA) Fellowship. Department of Anesthesiology and Perioperative Medicine. University of Pittsburgh; 2022. Available from: https://www.anesthesiology.pitt.edu/education/clinical-fellowships/adult-cardiothoracic-anesthesiology-acta-fellowship. Accessed November 21, 2022.
17. Stanford Health Care (SHC) - Stanford Medical Center. Types; 2020. Available from: https://stanfordhealthcare.org/medical-tests/e/echocardiogram/types.html. Accessed June 13, 2022.
18. Phoenix Heart Center. Echocardiograms: transthoracic (TTE) & Transesophageal (TEE); 2017. Available from: http://www.phoenixheartcenter.com/echocardiograms-tte-tee/. Accessed November 10, 2022.
19. de Bruijn SF, Agema WR, Lammers GJ, et al. Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischemic attack or stroke. Stroke. 2006;37(10):25312534. PMID: 16946152. doi:10.1161/01.STR.0000241064.46659.69
20. Thomsen J. To TTE or Tee? European Stroke Organisation; 2021. Available from: https://eso-stroke.org/to-tte-or-tee/#:~:text=TEE%20is%20considered%20more%20sensitive,visualization%20of%20left%20ventricular%20thrombus. Accessed October 24, 2022.
21. Kapral MK, Silver FL. Preventive health care, 1999 update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. Canadian Task Force on Preventive Health Care. CMAJ. 1999;161(8):989996. PMID: 10551199; PMCID: PMC1230713.
22. Noor A, Suffoletto M. An echocardiogram battle: tte vs tee in the diagnosis of infective endocarditis; 2019. Available from: https://shmabstracts.org/abstract/an-echocardiogram-battle-tte-vs-tee-in-The-diagnosis-of-infective-endocarditis/. Accessed November 10, 2022.
23. Johns Hopkins Medicine. Transesophageal echocardiogram; 2021. Available from: https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/transesophageal-echocardiogram. Accessed June 19, 2022.
24. UPMC. Echocardiography - purpose, types, and what to expect: UPMC in central PA. Available from: https://www.upmc.com/services/south-central-pa/heart-vascular/heart/diagnosis/screenings/echo. Accessed March 31, 2023.
25. Heart and Stroke Foundation of Canada. Transesophageal Echocardiogram (TEE); 2022. Available from: https://www.heartandstroke.ca/heart-disease/tests/transesophageal-echocardiogram-tee. Accessed June 19, 2022.
26. Stanford Health Care (SHC) - Stanford Medical Center. Transesophageal Echocardiogram (TEE); 2017. Available from: https://stanfordhealthcare.org/medical-tests/t/transesophageal-echocardiogram.html. Accessed June 19, 2022.
27. Transesophageal echocardiography (TEE); 2021. Available from: https://www.heart.org/en/health-topics/heart-attack/diagnosing-a-heart-attack/transesophageal-echocardiography-tee. Accessed November 10, 2022.
28. Memorial Sloan Kettering Cancer Center. About Your Transesophageal Echocardiogram (TEE). Available from: https://www.mskcc.org/cancer-care/patient-education/patient-guide-transesophageal-echocardiogram-tee. Accessed March 31, 2023.
29. Healthline, Healthline Media. Transesophageal Echocardiogram (TEE). Available from: https://www.healthline.com/health/tee-procedure#reasons. Accessed March 31, 2023.
30. Transthoracic Echocardiography (TTE) or Transesophageal. Available from: https://mountnittany.org/wellness-article/transthoracic-echocardiography-tte-or-transesophageal-echocardiography-tee-when-------your-child-needs. Accessed March 31, 2023.
31. American society of Anesthesiologist. Statement on transesophageal echocardiography; 2022. Available from: https://www.asahq.org/standards-and-guidelines/statement-on-transesophageal-echocardiography. Accessed June 19, 2022.
32. Poterack KA. Who uses transesophageal echocardiography in the operating room? Anesth Analg. 1995;80(3):454458. PMID: 7864407. doi:10.1097/00000539-199503000-00004
33. Peterson GE, Brickner ME, Reimold SC. Transesophageal echocardiography. Circulation. 2003;107(19):23982402. doi:10.1161/01.cir.0000071540.97144.89
34. DAIC. Advances in transesophageal echo. DAIC; 2021. Available from: https://www.dicardiology.com/article/advances-transesophageal-echo. Accessed June 13, 2022.
35. Chahine J, Montane B, Alzubi J, et al. Improved diagnostic performance of contemporary transesophageal echocardiography with three-dimensional imaging for infective endocarditis. Circulation. 2020;142(Suppl_3):A13434A13434. doi:10.1161/circ.142.suppl_3.13434
36. Maxwell C, Konoske R, Mark J. Emerging concepts in transesophageal echocardiography. F1000Res. 2016;5:F1000Faculty Rev340. PMID: 26998250; PMCID: PMC4792209. doi:10.12688/f1000research.7169.1
37. Fatima H, Sharkey A, Qureshi N, et al. Three-dimensional transesophageal echocardiography simulator: new learning tool for advanced imaging techniques. J Cardiothorac Vasc Anesth. 2022;36(7):20902097. PMID: 34275733. doi:10.1053/j.jvca.2021.05.050
38. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535
39. Hahn RT, Abraham T, Adams MS, et al. Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr. 2013;26(9):921964. PMID: 23998692. doi:10.1016/j.echo.2013.07.009
40. Rafferty T, LaMantia KR, Davis E, et al. Quality assurance for intraoperative transesophageal echocardiography monitoring: a report of 846 procedures. Anesth Analg. 1993;76(2):228232. PMID: 8424496. doi:10.1213/00000539-199302000-00005
41. Mishra M, Chauhan R, Sharma KK, et al. Real-time intraoperative transesophageal echocardiography--how useful? Experience of 5016 cases. J Cardiothorac Vasc Anesth. 1998;12(6):625632. PMID: 9854658. doi:10.1016/s1053-0770(98)90232-4
42. DiLorenzo MP, Bhatt SM, Mercer-Rosa L. How best to assess right ventricular function by echocardiography. Cardiol Young. 2015;25(8):14731481. doi:10.1017/S1047951115002255
43. Miller JP, Lambert AS, Shapiro WA, Russell IA, Schiller NB, Cahalan MK. The adequacy of basic intraoperative transesophageal echocardiography performed by experienced anesthesiologists. Anesth Analg. 2001;92(5):11031110. PMID: 11323329. doi:10.1097/00000539-200105000-00005
44. Sloth E, Pedersen J, Olsen KH, Wanscher M, Hansen OK, Srensen KE. Transoesophageal echocardiographic monitoring during paediatric cardiac surgery: obtainable information and feasibility in 532 children. Paediatr Anaesth. 2001;11(6):657662. PMID: 11696140. doi:10.1046/j.1460-9592.2001.00737.x
45. Bick JS, Jr DS, Kennedy JD, et al. Comparison of expert and novice performance of a simulated transesophageal echocardiography examination. Simul Healthc. 2013;8(5):329334. PMID: 24030477. doi:10.1097/SIH.0b013e31829068df
46. Sawasdiwipachai P, Thanasriphakdeekul S, Raksamani K, Vacharaksa K, Chaithiraphan V. Learning curve for the acquisition of 20 standard two-dimensional images in advanced perioperative transesophageal echocardiography: a prospective observational study. BMC Med Educ. 2022;22(1):412. PMID: 35637456; PMCID: PMC9153196. doi:10.1186/s12909-022-03280-3
47. Konstadt SN, Reich DL, Rafferty T. Validation of a test of competence in transesophageal echocardiography. J Cardiothorac Vasc Anesth. 1996;10(3):311313. PMID: 8725408. doi:10.1016/s1053-0770(96)80088-7
48. Sarrazin JF, Trottier M, Tessier M. Accuracy of PET/CT for detection of infective endocarditis: where are we now? J Nucl Cardiol. 2019;26(3):936938. PMID: 29143245. doi:10.1007/s12350-017-1126-2
49. Prendergast BD. Diagnostic criteria and problems in infective endocarditis. Heart. 2004;90(6):611613. PMID: 15145855; PMCID: PMC1768277. doi:10.1136/hrt.2003.029850
50. Pecoraro AJK, Herbst PG, Pienaar C, et al. Modified Duke/European Society of Cardiology 2015 clinical criteria for infective endocarditis: time for an update? Open Heart. 2022;9:e001856. doi:10.1136/openhrt-2021-001856
51. Mahmood M, Kendi AT, Ajmal S, et al. Meta-analysis of 18F-FDG PET/CT in the diagnosis of infective endocarditis. J Nucl Cardiol. 2019;26(3):922935. PMID: 29086386. doi:10.1007/s12350-017-1092-8
52. Ten HD, Slart RHJA, Sinha B, Glaudemans AWJM, Budde RPJ. 18F-FDG PET/CT in infective endocarditis: indications and approaches for standardization. Curr Cardiol Rep. 2021;23(9):130. PMID: 34363148; PMCID: PMC8346431. doi:10.1007/s11886-021-01542-y
53. Rouzet F, Iung B, Duval X, et al. 18F-FDG PET/CT in infective endocarditis. J Am Coll Cardiol. 2019;74(8):10411043. doi:10.1016/j.jacc.2019.06.049
54. Swart LE, Gomes A, Scholtens AM, et al. Improving the diagnostic performance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in prosthetic heart valve endocarditis. Circulation. 2018;138(14):14121427. PMID: 30018167. doi:10.1161/CIRCULATIONAHA.118.035032
55. Wang TKM, Snchez-Nadales A, Igbinomwanhia E, Cremer P, Griffin B, Xu B. Diagnosis of infective endocarditis by subtype using 18F-fluorodeoxyglucose positron emission tomography/computed tomography: a contemporary meta-analysis. Circ Cardiovasc Imaging. 2020;13(6):e010600. PMID: 32507019. doi:10.1161/CIRCIMAGING.120.010600
56. Orvin K, Goldberg E, Bernstine H, et al. The role of FDG-PET/CT imaging in early detection of extra-cardiac complications of infective endocarditis. Clin Microbiol Infect. 2015;21(1):6976. doi:10.1016/j.cmi.2014.08.012
See the rest here:
Interpretation Accuracy of Transesophageal Echocardiograms | VHRM - Dove Medical Press
These outpatient treatment centers offer higher rates of both provider and patient satisfaction, Biga said, in addition to delivering high-quality outcomes in a lower-cost setting. Medicare began reimbursing for ASC basic percutaneous coronary interventions (PCI) in 2020, which accelerated the growth of these centers. Regulations in some states favor OBLs or ASCs, so there has been a concentration of these centers in some states, mainly in the band from Florida across to country to the west to Arizona.
In some cases, larger hospital systems are even partnering with private companies that manage these labs to outsource their less complex cases and make room in the hospital cath labs for more involved (and more lucrative) procedures.
Biga said the Medicare fee schedule has changed in recent years to favor these outpatient centers for lower acuity patient care because they have much lower overhead costs than large hospital systems.The shift is being made for similar financial reasons asthe shift over the past decade from private cardiology practices to cardiologists increasingly being employed by the hospitals.
"There is a financial element to that you can't ignore, and the same is true here," Biga explained.
In many cases, OBLs and ASCs have the same equipment and often they have the same cardiologists at the area hospitals performing these procedures. She said the difference is just the location, which changes how much a procedure is reimbursed and how that translates into revenue when there are not a large number of additional costs that hospitals have to cover.
"Outcomes are probably just as good, if not better, and patient satisfaction tends to be much better because it is an easier in or out. If you go to a hospital and your are registering, it is a two-hour process. If you are in a smaller setting, it is a much better patient experience," Biga said.
Her biggest concern with these centers is that they meet the same patient safety and quality metrics as hospital facilities. Biga said this can be done if OBL and ASCs become a part of the ACC National Cardiovascular Data Registry (NCDR) like larger cath labs at hospitals. She said this would provide a benchmarking capability to measure the quality of the outpatient centers as compared to traditional care for similar types of patients and procedures. The ACC is presently working on a lighter version of the registry to support OBLs and ASCs.
See original here:
What the rise of outpatient cardiac OBLs and ASCs means for ... - Cardiovascular Business
March 20, 2023
1 min read
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Back to Healio
Experts at the Cardiovascular Translational Research Center at the University of South Carolina are leading research in hypertension to further advancements in CVD prevention.
Their efforts include investigations into the role of cell damage in hypertension and the relationship between changes in the vasculature and hypertension.
Healio spoke with R. Clinton Webb, PhD, director of the Cardiovascular Translational Research Center, about key topics in hypertension research. It was the top story in cardiology last week.
Another top story was about a study that found the level of inflammation better predicted future cardiovascular events or death than the level of LDL in patients at high cardiovascular risk who are already taking statin therapy. Researchers said the findings indicate that this population may need anti-inflammatory therapy just as much as cholesterol-lowering therapy to prevent cardiovascular events and death.
Read these and more top stories in cardiology below:
Hypertension research could yield advancements in CVD prevention
Hypertension is one of the most common risk factors for CVD, and despite numerous therapies existing, rates of uncontrolled hypertension have risen since the start of the COVID-19 pandemic. Read more.
Inflammatory risk better predicts events vs. cholesterol risk in statin-treated patients
In high-risk patients on statin therapy, residual inflammatory risk as assessed by high-sensitivity C-reactive protein better predicted cardiovascular events and death than residual cholesterol risk as assessed by LDL, data show. Read more.
Connections between neighbors of varying incomes tied to lower premature CV death
Increased neighborhood connectedness of people of lower and higher socioeconomic status via Facebook friendships was associated with lower county-level prevalence of cardiovascular death, a speaker reported. Read more.
Remote monitoring of cardiac devices during pandemic cut greenhouse gas emissions
Remote monitoring of more than 32,000 patients with cardiac implantable devices during the COVID-19 pandemic reduced greenhouse gas emissions by 12,596 metric tons compared with conventional monitoring, researchers reported. Read more.
Black women with genetic variant for amyloidosis face substantial CVD, mortality risk
Black female carriers of the V122I genetic variant for cardiac amyloidosis have substantially higher CVD and all-cause mortality risk, which grows with age, compared with noncarriers, researchers reported. Read more.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Back to Healio
Go here to see the original:
Top in cardiology: Updates in hypertension research; predictors of ... - Healio